KR20230040326A - A composition including complex extracts for improving joint health - Google Patents

Abstract

The present invention relates to: a functional health food composition for improving health of joints, which comprises, as active ingredients, two or more selected from a group consisting of a Taraxacum spp. extract, a Pueraria Flos extract, a Zingiber officinale Roscoe extract, Tetrahydrocurcumin, a Citrus unshiu extract, and a Boswellia serrata extract; a pharmaceutical composition for preventing and treating arthritis; and a quasi-drug composition for preventing and treating arthritis. The composition comprising two or more selected from a group consisting of a Taraxacum spp. extract, a Pueraria Flos extract, a Zingiber officinale Roscoe extract, Tetrahydrocurcumin, a Citrus unshiu extract and a Boswellia serrata extract has remarkably excellent effects of mitigating pains in joints and alleviating inflammation compared to a single material, thereby being effectively used in enhancing health of joints and preventing and treating arthritis.

Description

Composition for improving joint health comprising extracts of composite materials {A composition including complex extracts for improving joint health}

The present invention is Pogongyoung ( Taraxacum spp. ) Extract, Galhwa ( Pueraria Flos ) Extract, Ginger ( Zingiber officinale Roscoe ) Extract, Tetrahydrocurcumin ( Tetrahydrocurcumin ), Citrus unshiu ( Citrus unshiu ) Extract, and Boswellia serrata A health functional food composition for improving joint health, comprising two or more substances selected from the group consisting of extracts as active ingredients; A pharmaceutical composition for preventing or treating arthritis; And it relates to a quasi-drug composition for preventing or improving arthritis.

Arthritis is a disease that causes inflammation and pain in joints, and can be mainly divided into osteoarthritis (degenerative arthritis, osteoarthritis) and rheumatoid arthritis. First of all, osteoarthritis is that the cartilage layer developed inside the joint to relieve the shock and friction that occurs when bones collide directly with each other is damaged, causing pain as bones rub against each other directly, resulting in difficult joint movement. refers to a dying disease Osteoarthritis may occur in one joint, such as the knee, hip joint, hand, foot, or spine, or may occur simultaneously in several joints. Osteoarthritis is mainly caused by aging without a specific organic cause, and when it progresses chronically, it is accompanied by movement disorders such as gait disorder due to deformation of the joint structure. Looking at the mechanism, when osteoarthritis progresses, the production of proinflammatory cytokines such as TNF-α and IL-1 increases, and the secretion of MMPs such as collagenase and stromelysin increases, resulting in articular cartilage destruction will take place.

In particular, knee osteoarthritis has become a representative geriatric disease to the extent that 8 out of 10 people aged 65 or older in Korea suffer. Recently, the number of patients with knee osteoarthritis is gradually increasing even among relatively young people aged 40 to 50 years. It has been reported that the number of patients aged 40 to 64 increased from 1.6 million in 2011 to 2.1 million in 2015, an increase of 33%.

On the other hand, rheumatoid arthritis is an inflammatory disease characterized by polyarthritis, and autoimmunity is known as a major mechanism. Looking at the symptoms, as inflammation occurs in the synovial membrane tissue, macrophages, dendritic cells, T lymphocytes, and B lymphocytes migrate to the synovial tissue, and as a result, the joint fluid increases, causing pain as the joint swells. . When the inflammatory synovial tissue proliferates (hyperplasia) while this inflammation continues, bone and cartilage are destroyed, joint structure is deformed, and movement disorders occur. In addition, as in the progression of osteoarthritis, in rheumatoid arthritis, the production of inflammatory cytokines such as TNF-α and IL-1 increases, and the secretion of MMPs increases, thereby destroying collagen and proteoglycan to reduce articular cartilage is known to destroy

Although glucosamine is widely used as a material for preventing and treating arthritis and improving overall joint health, recently, according to the Ministry of Food and Drug Safety, glucosamine was designated as a subject for regular re-evaluation in 2018 to review its functionality and stability. However, doubts about its efficacy are growing. In this regard, although the intake of glucosamine shows some efficacy for mild cartilage damage, there is a problem in that the sensory effect is poor. In addition, MSM (Methylsulfonylmethane), which is used as a raw material for health functional foods because of its anti-inflammatory effect, also has limitations in its direct preventive and therapeutic effects on cartilage damage.

Therefore, in order to solve osteoarthritis and rheumatoid arthritis caused by complex factors, it prevents the more fundamental cause of cartilage tissue damage, relieves inflammation and pain caused by it, and finally improves joint health comprehensively and systematically. It is necessary to develop a composition that can

Under this background, the present inventors recognized the above problems and made diligent efforts to solve them. As a result, Taraxacum spp. Extract, Pueraria Flos extract, Zingiber officinale Roscoe extract, tetrahydrocurcumin ), dermis ( Citrus unshiu ) extract, and Boswellia ( Boswellia serrata ) Composition comprising two or more substances selected from the group consisting of extracts, compared to the single substance compared to the single substance significantly superior joint pain relief The present invention was completed by confirming that it is effective in improving joint health and preventing and treating arthritis by exhibiting effects and inflammation relief effects.

Korean Registered Patent No. 10-1095035 (2011.12.09)

One object of the present invention is for improving joint health, comprising as an active ingredient two or more substances selected from the group consisting of pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract. It is to provide a nutraceutical composition.

Another object of the present invention is to prevent or treat arthritis, comprising as active ingredients two or more substances selected from the group consisting of pogongyoung extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract. It is to provide a pharmaceutical composition for use.

Another object of the present invention is to prevent or prevent arthritis, which contains at least two substances selected from the group consisting of pogongyoung extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract as active ingredients. It is to provide a quasi-drug composition for improvement.

A detailed description of this is as follows. Meanwhile, each description and embodiment disclosed in this application may also be applied to each other description and embodiment. That is, all combinations of various elements disclosed in this application fall within the scope of this application. In addition, the scope of the present application is not to be construed as being limited by the specific descriptions described below.

One aspect of the present invention for achieving the above object comprises as an active ingredient two or more substances selected from the group consisting of pogongyeongyoung extract, brown flower extract, ginger extract, tetrahydrocurcumin, dermal extract and boswellia extract , Provides a health functional food composition for improving joint health.

In the present invention, 'Pogongyeong (蒲公英, Taraxacum spp.)' is a dried herb of a dandelion or a plant of the same genus in the Asteraceae family, specifically, Taraxacum platycarpum , Taraxacum mongolicum, Taraxacum mongolicum , Taraxacum sinicum, Taraxacum coreanum, Taraxacum albidum , Taraxacum aphrogenes , Taraxacum brevicorniculatum , Taraxacum Taraxacum californicum , Taraxacum centrasiaticum , Taraxacum holmboei , Taraxacum japonicum , Taraxacum officinale , Taraxacum coke - It may be Taraxacum kok-saghyz , Taraxacum laevigatum , Taraxacum erythrospermum , and more specifically Taraxacum platycarpum. Not limited to this. In the present invention, the Pogongyoung can be purchased commercially or cultivated or collected in the natural world without limitation. In oriental medicine, Pogongyoung is used to get rid of heat poison and boils, and can be used for eye congestion, acute hepatitis, jaundice, and symptoms of not being able to urinate due to fever. As for the pharmacological action, antibacterial action, immune function enhancement, bile secretion action, liver function protection action, and diuretic action have been reported.

In the present invention, 'galhwa (葛花, Pueraria Flos )' is a flower bud or a flower that has just begun to bloom of kudzu ( Pueraria lobata Ohwi ), and is also referred to as a brown algae (葛條花). The shape of the brown flower is uneven, long oval or bell-shaped, and is characterized by a unique smell and sweet taste. In the present invention, the brown flower may be purchased commercially, or grown or collected in nature, without limitation. It can be used for headaches, thirst, anorexia, abdominal distension, and vomiting due to excessive drinking.

In the present invention, 'ginger (生薑, Zingiber officinale Roscoe )' is a rhizome of a perennial herbaceous plant belonging to the ginger family, and has a unique fragrance and taste. 'Health (乾薑)' means the dried rhizome of ginger, and it is known to be effective in treating chills, fever, headache, vomiting, seawater, and phlegm caused by colds, and stomach pain and diarrhea caused by food poisoning. As pharmacological action, it has been reported that it promotes secretion of gastric juice, enhances digestion, stimulates the heart, promotes blood circulation, and sterilizes. In the present invention, the ginger or health may be purchased commercially, or grown or collected in nature, without limitation.

In the present invention, 'tetrahydrocurcumin (THC)' is a compound derived from turmeric (薑黃, Curcuma longa Linne ), the chemical formula is C ₂₁ H ₂₄ O ₆ , and the molecular weight is 372.41. According to a study published in PNAS in 2011, it was found that Escherichia coli, a commensal microorganism in the human intestine, has a very high curcumin conversion activity in relation to the curcumin metabolic pathway, and the metabolite produced in this metabolic process is THC. In addition, according to an in vivo study on the antioxidant effects of curcumin and THC (Okada et al Journal Of Nutrition. 2001), it was confirmed that compared to curcumin, THC is easily absorbed from the gastrointestinal tract and can be present in a larger amount in the body. THC is known to have antioxidant activity and cancer prevention effects. The 'turmeric' is a perennial herbaceous plant belonging to the ginger family, and its stems and roots are used for food and medicine. In oriental medicine, the rhizome is used as a herbal medicine, and it is known to be effective in pain relief and menstrual irregularity as a yellow medicine with a spicy and bitter taste. In the present invention, the turmeric may be purchased commercially, or cultivated or collected in nature, without limitation.

In the present invention, 'dermis' refers to the peel of a mature fruit of a tangerine tree ( Citrus unshiu Markovich or Citrus reticulata Blanco ), which is generally dried. It is also known by names such as hongpi (紅皮) and tangerine peel (橘皮). It has a peculiar smell, the taste is spicy and bitter, and the nature is warm. In oriental medicine, it is reported to strengthen the function of the spleen, promote digestion, expectorant, and have antibacterial action. In the present invention, the dermis can be purchased commercially, or grown or collected in nature, without limitation.

In the present invention, ' Boswellia serrata ' is also referred to as a frankincense tree as a dicotyledonous shrub of the olive family. The frankincense tree may be specifically, Boswellia carterii Birdwood, Boswellia sacra Flueckinger, or Boswellia serrata, but is not limited thereto. In the present invention, 'frankincense' means gum resin obtained by scratching the bark of the frankincense tree, and has a spicy and bitter taste. In oriental medicine, it is known to be used for abdominal pain, dysmenorrhea, bruises, muscle cramps, and malignant tumors due to its efficacy, such as relieving pain and getting rid of boils. In the present invention, the boswellia or frankincense can be purchased commercially, or grown or collected in nature, without limitation.

In the present invention, 'joint health' may be interpreted as meaning a condition without inflammation, damage, disease, etc., such as joints and cartilage constituting them, joint capsules, inside joints, connective tissue, ligaments, and synovial membranes, but is not limited thereto. no. Therefore, in the present invention, 'improvement of joint health' means pain caused by joint friction is reduced, joint inflammation is reduced, joint or cartilage wear or destruction is suppressed and recovery is promoted, or hyaluronic acid synthetase It may include, but is not limited to, joint lubrication due to promotion of expression and the like. Further, in the present invention, 'improvement of joint health' may include, without limitation, delayed onset or progression of joint diseases including osteoarthritis and rheumatoid arthritis, or improvement of symptoms due to the onset of the joint diseases.

In the present invention, 'arthritis' is a disease collectively referring to inflammatory changes in the joint caused by any cause such as bacteria or trauma, specifically, osteoarthritis, rheumatoid arthritis, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, gout, bacterial arthritis , juvenile rheumatoid arthritis, lupus, scleroderma, multiple sclerosis, fibromyalgia, polymyositis, dermatomyositis, Behçet's disease, Reiter's syndrome, Lyme arthritis, adhesive capsulitis, frozen shoulder, tendon synovitis, elbow capitis, Dquabane tendon synovitis, rheumatism It includes polymyalgia, adult-type Still's disease, etc., and more specifically, it may be osteoarthritis or rheumatoid arthritis, but is not limited thereto.

In the present invention, 'extract' refers to an extract obtained by extracting Pogongyeong, lignified ginseng, ginger, dermis, or boswellia, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or mixtures thereof, and extracts of all formulations that can be formed using the extract itself and the extract. Specifically, the extract of the present invention may be prepared and used in the form of a dry powder after extraction.

The type of extraction solvent used to extract the extract in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; or mixtures thereof may be used. Preferably, water, C1 to C4 lower alcohol, 1,3-butylene glycol, and ethyl acetate may be used alone or in combination of two or more, more preferably 70% ethanol may be used, but limited thereto It doesn't work.

In the present invention, a method for extracting the extract is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.

The manufacturing process of the extract of the present invention may include an extraction step, a drying step, a concentration step and a dilution step, but is not limited thereto. Specifically, in one production example of the present invention, 70% ethanol alcohol in an amount of 8 to 15 times the volume of Pogogonyoung was added, and extracted twice for 2 hours and 30 minutes at 75 ° C. to obtain an extract. The extract was first filtered, and the remaining liquid was evaporated, and the extract was concentrated and dried to obtain a dried product. Thereafter, 70% ethanol alcohol was added to the dried material again to dissolve it to a concentration of 7 to 10%, which was stored at 4 ° C. for 2 days and then filtered a second time. After secondary filtration, heat was applied at 110° C. for about 1 hour to obtain a concentrate. Finally, 70% ethanol alcohol was added and diluted so that the concentration of the concentrate was 5%, and the suspension was filtered to complete the preparation of the extract.

In the present invention, 'prevention' refers to any action that delays the onset or progression of arthritis or delays the occurrence of cartilage damage and joint inflammation by administration of the composition.

In the present invention, 'improvement' refers to any action that at least reduces the degree of arthritis symptoms, recovers damage to cartilage tissue, or reduces the occurrence of joint inflammation.

In the present invention, 'treatment' refers to all activities that improve or beneficially change symptoms due to the onset of arthritis by administration of the composition.

In the present invention, 'food' includes, for example, various foods, beverages, chewing gum, tea, vitamin complexes, health functional (sex) foods, etc., and includes all foods in a conventional sense. The food can be prepared in formulations such as tablets, granules, powders, capsules, liquid solutions and pills according to known manufacturing methods, and the content of the extract according to the present invention is 0.0001 based on the total weight of the food composition depending on the formulation It can be adjusted from wt% to 100 wt%. There is no particular limitation on other ingredients except for containing the extract according to the present invention as an active ingredient, and various conventional flavoring agents or natural carbohydrates may be included as additional ingredients.

Examples of the natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The proportion of the natural carbohydrate may be generally about 1 g to 20 g, specifically about 5 g to 12 g per 100 ml of the composition of the present invention.

In the present invention, 'health functional (sex) food' is the same term as food for special health use (FoSHU), and is medically processed to efficiently display bioregulatory functions in addition to nutritional supply, food with high medical effects. means The 'function (sex)' refers to obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation. In addition, the formulation of the health functional food may also be prepared without limitation as long as the formulation is recognized as food. The health functional food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, there is no side effect that may occur when taking a drug for a long time using food as a raw material, and has excellent portability.

Specifically, the health functional food is a food prepared by adding the composition of the present invention to food materials such as beverages, teas, spices, chewing gum, confectionery, etc., or encapsulated, powdered, suspended, etc. It means to bring about an effect, but unlike general drugs, it has the advantage of not having side effects that can occur when taking drugs for a long time by using food as a raw material.

The health functional food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited, and any carrier commonly used in the art may be used.

In addition, the health functional food composition may include additional components that are commonly used in food compositions to improve odor, taste, and visual properties. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chrome (Cr); and amino acids such as lysine, tryptophan, cysteine, and valine. In addition, the health functional food composition contains preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), Butylhydroxytoluene (BHT), etc.), coloring agent (tar colorant, etc.), coloring agent (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite, etc.), seasoning (MSG sodium glutamate, etc.), sweetener (dulcin, cyclemate, etc.) , saccharin, sodium, etc.), flavoring (vanillin, lactones, etc.), expanding agent (alum, D-potassium hydrogen tartrate, etc.), strengthening agent, emulsifier, thickener (thickener), coating agent, gum base agent, foam inhibitor, solvent, improver, etc. of food additives. The additive may be selected according to the type of food and used in an appropriate amount.

As an example of the health functional food composition of the present invention, it can be used as a health beverage composition, and in this case, it may contain various flavoring agents or natural carbohydrates as additional components like conventional beverages. The aforementioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrins and cyclodextrins; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as thaumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame may be used. The ratio of the natural carbohydrates may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 ml of the health drink composition of the present invention.

In addition to the above, the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain alcohol or a carbonating agent, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages, or vegetable beverages. These components may be used independently or in combination. The ratio of the components may be selected in the range of 0 part by weight to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

In the present invention, the composition containing two or more substances selected from the group consisting of pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract inhibits the production of PGE2 (Prostaglandin E2). can

In the present invention, 'PGE2 (Prostaglandin E2)' is one of a series of physiologically active substances having a prostanic acid skeleton, and is known to mediate reactions such as vasodilation, edema, fever and pain. In addition, PGE2 is secreted by the action of COX-2 and induces the production of matrix metalloproteinases (MMPs) in inflammatory diseases such as periodontitis and arthritis, and plays an important role in exacerbating inflammation or tissue destruction. In one embodiment of the present invention, the inhibitory effect of PGE2 production of pogongyoung, ginger, gall flower extract or THC was measured using an enzyme-linked immunosorbent assay (ELISA) kit.

In addition, in the present invention, a composition comprising two or more substances selected from the group consisting of pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract inhibits the expression of pro-inflammatory cytokines. it could be

In the present invention, 'proinflammatory cytokine' is a cytokine that promotes cell signaling and inflammatory response in the body, and is a substance that is mainly produced by activated macrophages and is involved in the upregulation of inflammatory responses (Zhang JM, An J 2007, "Cytokine, inflammation, and pain", International Anesthesiology Clinics, 45 (2): 27-37). Its types include tumor necrosis factor (TNF), IL-1, IL-6, IL-12, IL-18, and IFN-gamma. As the production of pro-inflammatory cytokines increases during the progression of arthritis, in one embodiment of the present invention, the expression of TNF-α, IL-1β, and IL-6 mRNA was measured using RT (real-time) PCR.

Another aspect of the present invention for achieving the above object includes at least two substances selected from the group consisting of pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract and boswellia extract as active ingredients To, it provides a pharmaceutical composition for preventing or treating arthritis.

In the present invention, 'pharmaceutical composition' refers to one prepared for the purpose of preventing or treating a disease, and may be formulated and used in various forms according to conventional methods.

The pharmaceutical composition of the present invention may include one or more active ingredients exhibiting the same or similar functions in addition to the above ingredients. The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, and calcium hydrogen phosphate. , Lactose, Mannitol, Taffy, Gum Arabic, Pregelatinized Starch, Corn Starch, Powdered Cellulose, Hydroxypropyl Cellulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Synthetic Aluminum Silicate, Stearic Acid, Magnesium Stearate, Aluminum Stearate, Calcium stearate, white sugar, dextrose, sorbitol and talc may be used. A pharmaceutically acceptable additive according to the present invention may be included in an amount of 0.1 to 90 parts by weight based on the composition, but is not limited thereto.

The pharmaceutical composition of the present invention can be administered in various oral and parenteral formulations during actual clinical administration. When formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. It can be prepared using Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient for the extract of the present invention, for example, starch, calcium carbonate, sucrose It may be prepared by mixing sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium styrate and talc may also be used. Liquid formulations for oral use include suspensions, solutions for oral use, emulsions and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin fat, glycerogeratin and the like may be used.

The pharmaceutical composition of the present invention can be administered orally or parenterally depending on the desired method, and in the case of parenteral administration, external skin or intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection Injection method can be selected. The dosage may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

The dosage of the pharmaceutical composition of the present invention varies in its range depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of the disease, and the daily dosage is Based on the amount of the extract, it may be 0.0001 mg/kg to 100 mg/kg, specifically 0.001 mg/kg to 10 mg/kg, and may be administered 1 to 6 times a day, but is not limited thereto.

Another aspect of the present invention for achieving the above object is to use two or more substances selected from the group consisting of pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract as active ingredients. It provides a quasi-drug composition for preventing or improving arthritis.

The 'quasi-drug composition' of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent as needed in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, aromatics, preservatives, and the like. can include

The quasi-drug composition of the present invention may include, but is not limited to, a disinfectant cleanser, shower foam, ointment, wet tissue, coating agent, etc. It can be appropriately selected from the description of.

The composition comprising two or more substances selected from the group consisting of pogongyeongyoung extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract of the present invention significantly improves joint pain relief compared to single substances. It can be effectively used for the improvement of joint health and the prevention and treatment of arthritis by exhibiting effects and inflammation relief effects.

Figure 1 is the degree of relief of knee pain when ingesting Pogongyoung extract, ginger extract, brown flower extract, THC, dermal extract, Boswellia extract, or a complex extract of 6 types (Pogongyoung, ginger, brown flower, THC, dermis and Boswellia) is shown.

Hereinafter, the configuration and effects of the present invention will be described in more detail through examples and experimental examples. These Examples and Experimental Examples are only for exemplifying the present invention, but the scope of the present invention is not limited thereto.

Example 1: Preparation of pogongyoung extract

An extract was obtained by adding 8 to 15 times 70% ethanol alcohol based on the volume of Pogongyeong Young, and extracting twice for 2 hours and 30 minutes at 75 ° C. The extract was first filtered to remove solids, the remaining liquid was evaporated to concentrate the extract, and dried to obtain a dried product. Thereafter, 70% ethanol alcohol was added once more to dissolve the dry matter so that the concentration was 7-10%, stored at 4° C. for 2 days, and then filtered a second time to remove precipitable substances. Thereafter, heat was applied at 110° C. for about 1 hour to obtain a concentrated concentrate, which was diluted with 70% ethanol alcohol to a final concentration of 5%. Finally, the suspended matter was filtered out of the diluted concentrate to complete the preparation of Porkongyoung extract.

Other extracts of lard, ginger, dermis, or boswellia were prepared according to the same process as the manufacturing process of the Pogongyoung extract.

Example 2: Preparation of THC (Tetrahydrocurcumin)

After re-extracting the turmeric extract prepared according to Example 1 using 70% ethanol alcohol at 60-65 ° C, the suspended matter is first filtered out. The extract was concentrated by heating at 50-55°C, washed with cold ethanol, hot ethanol was added to the resulting intermediate product, hydrogen was added thereafter, and secondary filtration was performed. Then, it was dried at 60-65° C. and then pulverized to finally separate and prepare THC.

Experimental Example 1: Joint pain relieving effect according to single intake of pogongyeong extract, brown flower extract, ginger extract, THC, dermal extract, boswellia extract and synergistic effect confirmed through combined intake

The joint pain relief effect of the composition of the present invention was verified. Specifically, 80 test subjects (VAS score of 5 or more, facial expression evaluation of 6 or more) who complained of knee pain among adult males and females aged 45 to 65 or older residing in Daejeon were selected, and from June 2017, Each extract was consumed alone or in combination over 4 weeks until July 2017, and the knee pain relief effect was evaluated.

To the test subjects, 200mg of pogongyeong extract, 200mg of brown flower extract, 200mg of ginger extract, 200mg of THC, 200mg of dermal extract, 200mg of boswellia extract, and 33.3mg of each of pogongyoung/galhwa/ginger/THC/dermal/boswellia extract were simply mixed. 200 mg of each composite extract was ingested. The experimental results are expressed as bars in Figure 1 for the overall pain reduction effect of the test subjects after ingestion of each extract. Specifically, using VAS (Visual Analog Scale), the degree of pain of the subjects before and after ingestion of each extract was listed on a scale of 0 to 10 in order from 'no pain' to 'extreme pain', and then the subjects were asked to select was measured. As a result, it was confirmed that the Pogongyoung/Galhwa/ginger/THC/dermal/Boswellia composite extract had a significantly better knee pain relieving effect than the single extract in all subjects.

Experimental Example 2: Confirmation of PGE2 production inhibitory effect according to single treatment or combined treatment of pogongyoung extract, brown flower extract, ginger extract, THC, dermal extract, and boswellia extract

Prostaglandin E2 (hereinafter referred to as PGE2) is secreted by the action of COX-2 and is known as a factor that exacerbates soft tissue inflammation. Accordingly, the PGE2 production inhibitory effect according to the single treatment or combined treatment of the pogongyeongyeong extract, brown flower extract, ginger extract, THC, dermal extract, and boswellia extract of Example 1 was measured. Murine macrophage cell line RAW 264.7 cells were purchased from the Korean Cell Line Bank (KCLB), and DMEM (Dulbecco's Modified Eagle's Medium) low glucose medium supplemented with 10% FBS (Fetal Bovine Serum) and 1% antibiotics was used in 5% CO Subculture was performed once every 2 to 3 days in a 37° C. incubator where ₂ exists. Then, the content of PGE2 in the RAW 264.7 cell culture medium was measured using an enzyme-linked immunosorbent assay (ELISA) kit. RAW 264.7 cells were dispensed into a 24-well plate at a concentration of 2 X 10 ⁵ cells/ml using DMEM low glucose medium, and each sample was mixed with 1 μg/mL of lipopolysaccharide (LPS), a bacterial inflammation-inducing substance. Inflammation was induced and cultured for 24 hours.

Pogongyoung extract, gall flower extract, ginger extract, THC, dermal extract, and boswellia extract were dissolved in DMSO at 5% (50 mg/ml), and then treated with 5, 10, 50, 100, and 200 ppm for each concentration in the cultured cells. did. In the case of complex treatment, 2 out of 6 types (Pogongyoung + Galhwa, Pogongyoung + Ginger, Pogongyeong + THC, Pogongyoung + Dermal, Pogongyoung + Boswellia, Gallhwa + Ginger, Gallhwa + THC, Gallhwa + Dermal, Galhwa + Boswellia , Ginger + THC, Ginger + Dermis, Ginger + Boswellia, THC + Dermis, THC + Boswellia, Dermis + Boswellia) at a ratio of 1:1, respectively, or Pogongyoung extract: Gall flower extract: Ginger extract: THC : Dermal extract : Boswellia extract = 1 : 1 : 1 : 1 : 1 : 1 The cultured cells were treated by concentration in the same manner as above. After 24 hours, the cell culture supernatant was taken and the amount of PGE2 produced was measured by ELISA. After confirming the effectiveness of each concentration of each raw material, the IC50 (The half maximal inhibitory concentration) was presented in Table 1.

As a result, the IC50 value was lower in the case of 2 types of complex treatment compared to the case of Pogogongyeongyeong extract, Galhwa extract, ginger extract, THC, dermal extract, and Boswellia extract alone, and especially in the case of 6 types of complex treatment, the IC50 value was It was found to be remarkably small at 0.5 ppm. From this, it was confirmed that the effect of inhibiting PGE2 production was significantly better when the complex treatment of the six substances was performed compared to the treatment of the extract and THC alone or the two composite treatments, and the composite extract of the six substances reduced the aggravation of soft tissue inflammation. It was confirmed that there is a significant effect in doing so.

Experimental Example 3: Confirmation of expression level of pro-inflammatory cytokines according to single treatment or combined treatment of pogongyeongyoung extract, brown flower extract, ginger extract, THC, dermal extract, and boswellia extract

Expressions of TNF-α, IL-1β, and IL-6 mRNAs, which are pro-inflammatory cytokines formed by LPS stimulation, were measured using real-time (RT) PCR. After taking the cell culture supernatant used in the ELISA experiment in Experimental Example 2, the remaining cells were recovered, total RNA was extracted with RNeasy mini kit (Qiagen), and 1 μg of RNA was quantified using GeneAmp® RNA PCR kit (Applied Biosystems) Reverse transcription was performed using . Reverse transcription reaction was performed using a Mycycler® PCR machine (Biorad). Afterwards, quantitative real time PCR was performed using 2 μl of the reverse transcription reaction solution and GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) Taqman® probe (Invitrogen, USA, Hs00193435_m1, Hs00193436_m1). Real-time PCR was performed using a CFX96 TouchTM Real-Time PCR Detection System (Biorad). Experimental results obtained through real-time PCR were based on GAPDH, a housekeeping gene, and Livak K.J. (Methods, 2001, 25, 402-408), the gene expression of the negative control group was set as 100%, and the result was processed, and each sample was processed by concentration (5, 10, 50, 100, 200ppm) The anti-inflammatory ability of the samples for pro-inflammatory cytokine mRNA increased by LPS stimulation was reduced to IC50 (The half maximal inhibitory concentration) and shown in Table 2.

As a result, the IC50 values of IL-1β, IL-6, and TNF- It was found to be significantly smaller for α, and from this, it was confirmed that the effect of suppressing the expression of pro-inflammatory cytokines was significantly better when the six substances were treated in combination compared to the extract, THC alone, or when the two were combined.

From the above description, those skilled in the art to which this application pertains will be able to understand that this application can be implemented in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present application should be construed as including all changes or modifications derived from the meaning and scope of the following patent claims and their equivalent concepts rather than the detailed description above.

Claims (7)

Taraxacum spp. extract, Pueraria Flos extract, ginger ( Zingiber officinale Roscoe ) extract, tetrahydrocurcumin, Citrus unshiu extract, and Boswellia serrata A health functional food composition for improving joint health, comprising an extract as an active ingredient.
The functional food composition for improving joint health according to claim 1, wherein the extract is extracted with water, C1 to C4 lower alcohol, 1,3-butylene glycol, ethyl acetate or a mixed solvent thereof.
The functional food composition for improving joint health according to claim 2, wherein the lower alcohol is methanol, ethanol, propanol or butanol.
The functional food composition for improving joint health according to claim 1, wherein the composition inhibits the production of PGE2 (Prostaglandin E2).
The functional food composition for improving joint health according to claim 1, wherein the composition inhibits the expression of pro-inflammatory cytokines.
A pharmaceutical composition for preventing or treating arthritis, comprising pogongyeong extract, gall flower extract, ginger extract, tetrahydrocurcumin, dermal extract, and boswellia extract as active ingredients.
A quasi-drug composition for preventing or alleviating arthritis, comprising Pogongyoung extract, Galhwa extract, ginger extract, tetrahydrocurcumin, dermal extract, and Boswellia extract as active ingredients.

Images